<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yi K</submitter><funding>National Natural Science Foundation of China</funding><pagination>2256671</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9110163</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2022</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Yiqi Yangjing prescription (YQYJ) is a traditional Chinese medicine prescription used for treating lung cancer. It has a significant effect on enhancing efficacy, reducing toxic symptoms, and improving patients' physical well-being. The effective inhibitory effect on nonsmall-cell lung cancer (NSCLC) has been demonstrated &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i>. However, the mechanism of action and the material basis still remain unclear.&lt;h4>Methods&lt;/h4>In this study, we explored this mechanism using network pharmacology, after which we explored the pharmacodynamics and the action mechanism of YQYJ using cell viability evaluation, plate clone formation assay, flow cytometry, real-time quantitative PCR, and Western blot.&lt;h4>Results&lt;/h4>The enrichment results showed that there </pubmed_abstract><journal>Evidence-based complementary and alternative medicine : eCAM</journal><pubmed_title>The Core Mechanism of Yiqi Yangjing Decoction Inhibiting Nonsmall-Cell Lung Cancer.</pubmed_title><pmcid>PMC9110163</pmcid><funding_grant_id>82004278</funding_grant_id><pubmed_authors>Yi K</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Zhang M</pubmed_authors><pubmed_authors>Zhou Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Core Mechanism of Yiqi Yangjing Decoction Inhibiting Nonsmall-Cell Lung Cancer.</name><description>&lt;h4>Background&lt;/h4>Yiqi Yangjing prescription (YQYJ) is a traditional Chinese medicine prescription used for treating lung cancer. It has a significant effect on enhancing efficacy, reducing toxic symptoms, and improving patients' physical well-being. The effective inhibitory effect on nonsmall-cell lung cancer (NSCLC) has been demonstrated &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i>. However, the mechanism of action and the material basis still remain unclear.&lt;h4>Methods&lt;/h4>In this study, we explored this mechanism using network pharmacology, after which we explored the pharmacodynamics and the action mechanism of YQYJ using cell viability evaluation, plate clone formation assay, flow cytometry, real-time quantitative PCR, and Western blot.&lt;h4>Results&lt;/h4>The enrichment results showed that there </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-04-08T17:49:42.32Z</modification><creation>2025-02-19T01:54:56.219Z</creation></dates><accession>S-EPMC9110163</accession><cross_references><pubmed>35586682</pubmed><doi>10.1155/2022/2256671</doi></cross_references></HashMap>